Carcinoma of the uterine cervix is one of the leading cancers among women in our country. This invasive disease is preceded by a number of precancerous conditions detectable by a cytological screening method called as Pap smear. If the precancerous changes in cervical tissue (which can linger for years) are identified and successfully treated, the lesions will not develop into cancer. So, the pathway of preventing cervical cancer deaths is simple and effective. The present article describes the recent ideas about classification and management approach of these precancerous lesions. 
Introduction
Cervical cancer is the most common malignancy in women and is undoubtedly the only cancer that is potentially preventable. Global efforts to prevent the disease have focused on screening women using Pap smears (named for inventor Dr George Papaniculaou) and treating precancerous lesions. Pap smear screening, also called cytological screening, has achieved impressive results in reducing cervical cancer incidence and mortality in some developed countries. But in developing countries like ours, where approximately 80% of all new cases occurmany women have never had a Pap smear. A well planned cytological screening program with an intensive infrastructural support is essential to reduce the incidence of this preventable disease in our country. Most if not all, cases of preinvasive and invasive cervical disease are caused by human papilloma virus, which is spread by sexual contact. The virus infects cells in the transformation zone, the junction between the ectocervix and endocervix, causing nuclear atypia, dysplasticappearing cells and in rare cases, cancer. Early precancerous changes can be detected by cervical Pap smears and effectively treated. To achieve this a system of adequate follow-up must be established.
Pap smear-an overview
A Pap smear is a cytological test designed to detect abnormal cervical cells. The procedure involves scrapping cells from the cervix and then smearing and fixing them on a glass slide. Slides are then evaluated by a competent cytologist who determines the cell classification.
The Pap smear is generally considered to be a very specific test for high-grade lesions or cancer. Sensitivity is the proportion of women correctly identified by the test as having these conditions. The accuracy of a normal (or negative) cervical smear result, if the specimen is properly taken and reliably screened and interpreted, gives good protection against development of cervical cancer within the next three to five years, but it does not completely exclude the presence of small areas of usually low grade CIN. Colposcopic examination and cervicography are more sensitive tests for CIN, but they are not practical screening procedures, because they are too sensitive and would involve too many women in largely unnecessary investigations and treatment for small mostly low grade CIN and HPV infection. In general, it is not possible to increase pap smears. While these approaches appear promising, they are expensive and rely heavily on technology. 3 4 
Screening Recommendations
A. Whom to test * All women who are sexually active. * All women over eighteen years of age. 
B. When to test

Pap smear classification system
One of the big difficulties in discussing Pap smears is the mixing and matching of different classification systems that have been used through out the years. The first system was a "Class" system and that was followed by a "Dysplasia" system. Then came a "CIN" classification and finally the currently used "Bethesda" system. It often takes years, however, for pathologists and clinicians to make full transitions to the new terminology without including terminology from or referencing to past classification systems. To better guide the treatment of precancerous cervical changes, a simplified system of classifying these early lesions-the Bethesda system has been established in 1991. A more refined form of this system -the Bethesda 2001 Pap smear classification system has been introduced very recently. A comparison of the different terminologies (Table-1 ) and the most recent system (Table-2 With the strengthening of cytological screening programs, pre-malignant lesions of the cervix are being increasingly identified. These need to be treated effectively for any real impact on cervical cancer incidence and mortality. As with any screening test, the actual microscopic changes in the cervical tissue can be worse than the cells picked up on pap indicate or they can be the same or even less abnormal. To tell what the actual changes are, a cervical biopsy is needed in which the tissue is viewed under the microscope. Doctors, however, should not always recommend cervical biopsies for abnormal Pap smears because of the abnormal Paps will regress to normal on their own. 5 Some key points are described below for a better management of precancerous lesions.
Squamous cell Abnormality
ASCUS (Atypical squamous cells of undetermined significance)-
The test should be repeated at 4-6 months interval until three consecutive normal Pap smears, then return to annual screening. 5 ' 9 If any repeat smear reveal ASCUS, Patient should be referred to a Gynaecologist for colposcopy.
LSI L (CIN-I or mild Dysplasia, and/or HPV cytopathic changes)
should have a repeat smear after 3-6 months in an asymptomatic woman. If the same grade of abnormality persists for two or three smears, referral for colposcopy is indicated 6 ' 10 HPV lesions may regress spontaneously, persist for long periods but about 30% of such lesions will progress to CIN within 6-18 months.' It is important to be aware of the relatively poor sensitivity of the smear test in the presence of invasive cervical cancer and to advice examination by a Gynaecologist even for a mild dyskaryotic smear if there is abnormal bleeding or discharge". It should also be kept in mind that a small proportion of LSIL might reveal HSIL on colposcopy 7 . Hence in symptomatic patients immediate colposcopy and biopsy is indicated. 
HSIL (CIN
FEW WORDS ABOUT COLPOSCOPY AND CONE BIOPSY
The use of colposcope allows the clinician to examine the cervix under magnification and to make a directed biopsy. With satisfactory colposcopy, the prediction values of the directed biopsies are excellent.
In our country however, colposcopic facility is not available everywhere and in that case a diagnostic cone biopsy is indicated. Though cone biopsy carries a risk of morbidity and complications in the patient it is the major diagnostic and preventive measure to be adopted at present in our set up.
Cone biopsy has got few other indications alsoi) Unsatisfactory colposcopy-where the cervical transformation zones is not visible.
ii) When a colposcopic biopsy has a lower grade of abnormality than the cytology and colposcopy.
iii) When Endocervical Adenocarcinoma is suspected.
In our country, no effective screening program is available till now and treatment options are also very limited. To develop an effective barrier to the disease a strong infrastructural setup for screening and management is necessary. As cervical carcinoma is the only cancer that is potentially preventable and as this is the leading cause of death from cancer among our women; we should take immediate measures to reduce the incidence of this preventable disease.
